medigraphic.com
ISSN 1405-1699 (Impreso)
Órgano Oficial del Colegio Mexicano de Alergia, Asma e Inmunología Pediátrica y de la Asociación Latinoamericana de Pediatría

2003, Número 2

<< Anterior Siguiente >>

Alerg Asma Inmunol Pediatr 2003; 12 (2)


Eosinófilos: Revisión de la literatura

Brito GF, Yamazaki MA, Espinosa PSS, Vázquez TO

Idioma: Español
Referencias bibliográficas: 41
Paginas: 11-17
Archivo PDF: 278.30 Kb.


RESUMEN

El eosinófilo es un granulocito pequeño derivado de la médula ósea, tiene una vida media en la circulación de 6 a 12 horas antes de migrar a los tejidos en donde permanece por varios días, su desarrollo en la médula ósea es estimulado por interleucina-5, interleucina 3 y factor estimulante de colonias granulocito-macrófago. Su núcleo bilobulado es característico y sus gránulos citoplásmicos son distintivos, estas proteínas granulares son responsables de muchas funciones proinflamatorias, principalmente en la patogénesis de las enfermedades alérgicas, como célula efectora de hipersensibilidad inmediata, así como en la muerte de parásitos. Los eosinófilos interactúan con otras células por la expresión de múltiples receptores en su superficie.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Hoffman HM, Broide DH. Eosinophilia in children’s. Immunol Clin North Am 1997; 17(2):25-53.

  2. Brigden ML. A practical workup for eosinophilia. The Practical Peer-Reviewed Journal for Primary Care Physicians on line. 1999.

  3. Holgate ST. Allergy. Second ed. Textbook 2001.

  4. Mustafa Demirci, Metin Korkmaz. Diagnostic importance of serological methods and eosinophilia in tissue parasites. J Health Popul Nutr 2002; 20(4): 352-355.

  5. Rothemberg ME. Eosinophilia. New Engl J Med 1998; 388: 1592-600.

  6. Molinier S, Chaudier B, Kraemer P, Griffin B, San VV, Imbert P. Diagnostic and treatment of hypereosinophilia upon return from the tropics: 102 patients. Med Trop 1998; 58(Suppl. 4): 499-502.

  7. Wolfe MS. Eosinophilia in the returning traveler. Med Clin North Am 1999; 83: 1019-32.

  8. Gillespie SH, Bidwell D, Voller A, Robertson BD, Maizels RM. Diagnosis of human toxocariasis by antigen capture enzyme linked immunobsorbent assay. J Clin Pathol 1993; 46: 551-4.

  9. López M, Salvaggio JE. Eosinophilic pneumonias. Immunol Allergy Clin North Am 1992; 12: 349-63.

  10. Tuneu. El eosinófilo. Estructura, función y su participación en patología cutánea. Piel 1987; 2: 233-240.

  11. Frigas E, Loegering DA, Gleich GJ. Citotoxic effects of the guinea-pig eosinophil major basic protein on tracheal epithelium. Lab Invest 1998; 42: 35-40.

  12. Zucker-Franklin D. Eosinophil function related to cutaneous disorders. J Invest Dermatol 1998; 71: 100-105.

  13. Brigden ML, Horak MG. Incidence and clinical significance of unsuspected eosinophilia discovered by automated WBC differential counting. Lab Med 1993; 24(3): 173-6.

  14. Wardlaw AJ. Eosinophils in the 1990s: new perspectives on their role in health and disease. Postgrad Med J 1994; 70(826): 536-52.

  15. Spry CJ. Eosinophilia Practitioner. 1982; 226(1363): 119-27.

  16. Lokich J. Clinical problem-solving: hipereosinophilic syndrome. N Engl J Med 1996; 334(8): 538-40.

  17. Weller PF. The immunobiology of eosinophils. N Engl J Med 1991; 324(16): 1110-8.

  18. Weller PF, Bubley GJ. The idiopathic hypereosinophilic syndrome. Blood 1994; 83(10): 2759-79.

  19. Maidment I, Psych D, Williams C. Drug-induced eosinophilia. The Pharmaceutical Journal 2000; 264(7078): 71-76.

  20. Breen EC, Rezai AR, Nakajima K. Infection with HIV is associated with elevated IL-6 levels and production of eosinophilia. J Immunol 1990; 144: 480.

  21. Allen JN, Davis WB. Eosinophilic lung diseases. Am J Respir Crit Care Med 1994; 150: 1423-38.

  22. Cohen AJ, Steigbigel RT. Eosinophilia in patients infected with human immunodeficiency virus. J Infect Dis 1996; 174(3): 615-8.

  23. Lucey DR, Clerici M, Shearer GM. Type 1 and Type 2 cytokine dysregulation in allergic diseases. J Aller Immunol 1999; 13(170): 25-30.

  24. Lucey D. Workup for eosinophilia. Medicine 2002.

  25. Wardlaw AJ. Molecular basis for selective eosinophil trafficking in asthma: a multistep paradigm. J Allergy Clin Immunol 1999; 104: 917-26.

  26. de Vries JE. The role of IL-13 and its receptor in allergy and inflammatory responses. J Allergy Clin Immunol 1998; 102: 165-9.

  27. Horie S, Okubo Y, Hossain M, Sato E, Nomura H, Koyama S et al. Interleukin -13 but not interleukin -4 prolongs eosinophil survival and induces eosinophil chemotaxis. Intern Med 1997; 36: 179-85.

  28. Uttmann W, Knoechel B, Foerster M, Matiz H, Virchow JC Jr, Kroegel C. Activation of human eosinophils by IL-13. Induction of CD69 surface antigen, its relationship to messenger RNA expression, and promotion of cellular viability. J Immunol 1996; 157: 1678-83.

  29. Pope M, Brandt EEB, Mishra AA, Hogan SP, Zimmerman N, Matthaei KI. IL-13 induces eosinophil recruitment into the lung by IL-5 and eotaxin-dependent mechanism. J Allergy Clin Immunol 2001; 108: 594-601.

  30. Wills-Karp M, Luyimbazi J, Xu X, Schofiel B, Neben TY, Karp CL. Interleukin-13: central mediator of allergic asthma. Science 1998; 282: 2258-61.

  31. Gurjit K, Khurana H. IL-13 receptors and signaling pathways: an evolving web. J Allergy Clin Immunol 2003; 111: 677-90.

  32. Miike S, Kita H. Human eosinophils are activated by cisteine proteases and release inflammatory mediators. J Allergy Clin Immunol 111: 704-13.

  33. Menzies-Gow A, Flood-Page P, Sehmi R, Burman J, Hamid Q, Robinson DS, Kay AB, Denburg J. Anti-IL-5 therapy induces bone marrow eosinophil maturational arrest and decreases eosinophil progenitors in the bronchial mucosa of atopic asthmatics. J Allergy Clin Immunol 2003; 111: 714-9.

  34. Palframan RT, Collins PD, Severs NJ, Rothery S, Williams TJ, Rankin SM. Mechanisms of acute eosinophil mobilization from the bone marrow stimulated by interleukin -5: the role of specific adhesion molecules and phosphatidylinositol 3- kinase. J Exp Med 1998; 188: 1621-32.

  35. Bosquet J, Chanez P, Lacoste JY, Barneon G, Ghavanian N, Demander I. Eosinophilic inflammation in asthma . N Engl J Med 1990; 323: 1033-9.

  36. Denburg JA, Sehmi R, Saito H, Pil-Seob J, Inman M, O Byrne PM. Systemic aspects of allergic disease: bone marrow responses. J Allergy Clin Immunol 2000; 106: S242-6.

  37. Ogawa M. Differentiation and proliferation of hematopoietic stem cells. Blood 1993; 81: 2844-53.

  38. Foster PS, Hogan SP, Yang M, Young IG, Matthaei KI, Kumar RK. Interleukin-5 and eosinophils as therapeutic targets for asthma. Trends Mol Med 2002; 8: 162-7.

  39. Butterfield JH, Leiferman KM, Gleich GJ. Eosinophil-associated diseases. In: Frank MM, Austen KF, Claman HN, Unanue ER. Samter’s Immunologic diseases. Boston: Little, Brown and Co. 1995; I: 501-527.

  40. Lee T, Lenihan DJ, Malone B, Roddy LL, Waserman SI. Increased biosyntheses of platelet-activating factor in activated human eosinophils. J Biol Chem 1984; 259: 5526-30.

  41. Hackemiller R, Kim J, Feldman RA, Simon MC. Abnormal Stat activation, hematopoietic homeostasis, and innate immunity in c-fes/mice. Immunity 2000; 13: 397-407.




2020     |     www.medigraphic.com